Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGenmab AS

Genmab AS

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
55.8 USD 2.17 ( 4.05%)
Last update at 2026-11-09T21:07:00Z
VOLUME
5044857
Market Cap
20998.92M
P/E
27.10

Momentum Score

…

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
53.31
Low
55.91
High
52 Week Price Range
23.62
Low
35.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Genmab A/S is a Danish biotechnology company focused on discovering and developing antibody therapeutics for oncology and hematology, and it generates revenue primarily through royalties and collaborations with larger drug developers. Long-term growth drivers include royalties from marketed products, advancement of an internal bispecific-focused pipeline, and licensing of antibody-platform technologies, which may benefit investors seeking recurring revenue and clinical upside.
Key risks are reliance on a few partnered marketed products for royalties, clinical and regulatory setbacks for its pipeline, and competitive or patent pressures that could reduce future revenue.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
53.63
Dividend Yield
-
Revenue TTM
4131.00M
Revenue Per Share
6.71
Gross Profit TTM
3843.00M
Debt / Equity
0.93
ROE
14.00%
Net Debt
3714.91M
ROCE
10.95%
Diluted EPS TTM
1.26

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1204.95M 9164.00M 5637.00M 7035.00M 3983.00M
Net income 963.76M 7844.00M 4352.00M 5522.00M 3008.00M
Selling general administrative 626.00M 3790.00M 3297.00M 2676.00M 1283.00M
Gross profit 3413.69M 20541.00M 16248.00M 14595.00M 8482.00M
Reconciled depreciation 71.00M 413.00M 295.00M 362.00M 248.00M
Ebit 1250.99M 9284.00M 5707.00M 6357.00M 3018.00M
Ebitda 1322.04M 9697.00M 5947.00M 7043.00M 3463.00M
Depreciation and amortization 71.06M 413.00M 240.00M 686.00M 445.00M
Operating income 1250.99M 6703.00M 5321.00M 6357.00M 3018.00M
Other operating expenses 2471.95M 14823.00M 11153.00M 8238.00M 5464.00M
Interest expense 61.05M 120.00M 27.00M 21.00M 13.00M
Tax provision 241.00M 1320.00M 1285.00M 1513.00M 975.00M
Interest income 138.00M 995.00M 939.00M 324.00M 197.00M
Net interest income 77.00M 875.00M 912.00M 303.00M 184.00M
Income tax expense 241.19M 1320.00M 1285.00M 1513.00M 975.00M
Total revenue 3722.93M 21526.00M 16474.00M 14595.00M 8482.00M
Total operating expenses 2162.70M 13838.00M 10927.00M 8238.00M 5464.00M
Cost of revenue 309.24M 985.00M 226.00M - -
Total other income expense net -46.04M 2461.00M 316.00M 678.00M 965.00M
Net income from continuing ops 963.00M 7844.00M 4352.00M 5522.00M 3008.00M
Net income applicable to common shares - - - 5522.00M 3008.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 12843.63M 45811.00M 35289.00M 30278.00M 24627.00M
Intangible assets 9102.19M 12343.00M 101.00M 146.00M 254.00M
Other current assets 0.00M 101.00M - - -
Total liab 7009.97M 9114.00M 3679.00M 2837.00M 2431.00M
Total stockholder equity 5833.66M 36697.00M 31610.00M 27441.00M 22196.00M
Other current liab 42.24M 3482.00M 54.00M 1716.00M 1130.00M
Common stock 9.98M 66.00M 66.00M 66.00M 66.00M
Capital stock 10.00M 66.00M 66.00M 66.00M 66.00M
Retained earnings 4088.65M 23551.00M 19023.00M 14968.00M 10020.00M
Other liab - - - 491.00M 500.00M
Good will 354.19M 2535.00M - - -
Other assets - - - 300.00M 291.00M
Cash 1711.09M 9858.00M 14867.00M 9893.00M 8957.00M
Total current liabilities 1423.74M 5308.00M 2484.00M 1823.00M 1568.00M
Current deferred revenue 23.95M 24.00M 33.00M 33.00M 26.00M
Net debt 3714.91M -8829.00M -14097.00M -9296.00M -8532.00M
Short term debt 291.00M 92.00M 90.00M 74.00M 62.00M
Short long term debt 273.00M - - - -
Short long term debt total 5426.00M 1029.00M 770.00M 597.00M 425.00M
Other stockholder equity 1915.62M 12590.00M 12461.00M 12309.00M 12029.00M
Property plant equipment - - - 1322.00M 975.00M
Total current assets 2878.42M 27854.00M 33139.00M 28377.00M 22736.00M
Long term investments 37.00M 228.00M 134.00M 133.00M 371.00M
Net tangible assets - - - 27295.00M 21942.00M
Short term investments 0.00M 11243.00M 13268.00M 12431.00M 10381.00M
Net receivables 1149.37M 6691.00M 4947.00M 6053.00M 3398.00M
Long term debt 5001.00M - - - -
Inventory 17.96M 62.00M 57.00M - -
Accounts payable 1066.56M - 2307.00M - 350.00M
Accumulated other comprehensive income -180.59M 490.00M 60.00M 98.00M 81.00M
Non currrent assets other 0.00M 2460.49M - 48.00M 27.00M
Non current assets total 9965.21M 17957.00M 2150.00M 1901.00M 1891.00M
Capital lease obligations 152.00M 1029.00M 770.00M 597.00M 425.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1627.00M -9907.00M -976.00M -2761.00M -709.00M
Change to liabilities - - - 283.00M 304.00M
Total cashflows from investing activities -5647.45M -9907.00M -1282.00M -2761.00M -961.00M
Net borrowings -13.00M -8.37M -13.51M -73.00M -58.00M
Total cash from financing activities 4792.78M -3919.00M -606.00M -789.00M -420.00M
Change to operating activities - - - - -770.00M
Net income 963.76M 7844.00M 5637.00M 7035.00M 3983.00M
Change in cash 345.33M -5009.00M 4974.00M 936.00M 1697.00M
Begin period cash flow 1365.76M 14867.00M 9893.00M 8957.00M 7260.00M
End period cash flow 1711.09M 9858.00M 14867.00M 9893.00M 8957.00M
Total cash from operating activities 1186.94M 7771.00M 7380.00M 3912.00M 2228.00M
Issuance of capital stock 5500.00M 0.00M 0.00M - 0.00M
Depreciation 71.06M 413.00M 295.00M 362.00M 248.00M
Other cashflows from investing activities - -117.00M -10.00M - -
Change to inventory -9.01M -5.00M -57.00M - -
Change to account receivables -166.13M -1590.00M 797.00M -2213.00M -1074.00M
Sale purchase of stock -430.34M -3988.00M -564.00M -908.00M -447.00M
Other cashflows from financing activities -31.02M 129.00M 49.00M 192.00M 85.00M
Change to netincome - - - -78.00M -314.00M
Capital expenditures 37.03M 187.00M 376.00M 317.00M 252.00M
Change in working capital 225.18M -1595.00M 1362.00M -1930.00M -770.00M
Stock based compensation 128.00M 721.00M 586.00M 439.00M 310.00M
Other non cash items -73.06M 388.00M -622.00M -1994.00M -997.00M
Free cash flow 1149.91M 7584.00M 7004.00M 3595.00M 1976.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GMAB
Genmab AS		 2.17
4.05%		 55.80 27.10 18.90 5.08 3.37 5.80 18.87
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Genmab AS

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

45 70 20 27 28

https://www.genmab.com

3119

Name Title Year Born
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, Pres & CEO 1961
Mr. Anthony Pagano Exec. VP & CFO 1978
Mr. Anthony Mancini Exec. VP & COO 1971
Dr. Judith V. Klimovsky M.D. Exec. VP & Chief Devel. Officer 1958
Dr. Tahamtan Ahmadi Exec. VP, Chief Medical Officer & Head of Experimental Medicines 1973
Dr. Mijke Zachariasse Ph.D. Director of Protein Production & Chemist and Non-Independent Director 1974
Dr. Rima Bawarshi Nassar Ph.D. VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director 1953
Mr. Peter Ros Sr. Director of Fin. & Accounting NA
Mr. Andrew Carlsen Sr. Director, VP & Head of Investor Relations NA
Ms. Birgitte Stephensen M.Sc. Exec. VP & Chief Legal Officer 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…